A four-gene risk assessment model involving CLDN4, SEMA3G, CAT, and UCN suggests that the high-risk group may exhibit higher sensitivity to immune therapy checkpoint inhibitors PD1, CTLA-4, IL-6, and LAG3 in ccRCC patients [150]. The gene discussed is LAG3; the disease is nonpapillary renal cell carcinoma.